CURE Pharmaceutical Receives Patent Approval for Its CUREfilm Blue™ Technology

Rhea-AI Summary

CURE Pharmaceutical Holding Corp. (OTC: CURR) announced the upcoming issuance of U.S. Patent No. 11,179,331 for its product CUREfilm Blue™, an oral soluble film containing sildenafil citrate, aimed at treating erectile dysfunction (ED). This innovative drug delivery method utilizes CURE's proprietary CUREfilm™ technology, enhancing patient experience with discreet and convenient administration. The erectile dysfunction drug market is projected to reach approximately USD$6.6 billion by 2025, with significant growth expected for sildenafil.

Positive

• Issuance of U.S. Patent No. 11,179,331 for CUREfilm Blue™, indicating strong intellectual property protection.
• CUREfilm Blue™ utilizes innovative delivery technology, potentially improving patient adherence and experience.
• The erectile dysfunction drug market is projected to grow at 6% CAGR, potentially benefiting CURR's market position.

Negative

• None.

OXNARD, Calif.--(BUSINESS WIRE)-- CURE Pharmaceutical Holding Corp. (OTC: CURR), a technology focused, vertically integrated drug delivery and product development company focused on pharmaceutical and health & wellness products, announced today that it received an issue notification from the U.S. Patent Office (USPTO) stating that U.S. Patent No. 11,179,331 (the ’331 patent) is set to issue on November 23, 2021. The ’331 patent, entitled “Oral Soluble Film Containing Sildenafil Citrate,” covers the product CUREfilm Blue™, an oral soluble film of sildenafil citrate (the active ingredient present in Viagra^®1) for the treatment of erectile dysfunction (ED). CURE is seeking approval of this product via the 505(b)(2) regulatory pathway.

CUREfilm Blue™ utilizes the Company’s patented and proprietary fast-dissolving drug delivery platform, known as CUREfilm™, to deliver the active pharmaceutical ingredient (API) sildenafil citrate. By innovating beyond the traditional pharmaceutical delivery of pills and solutions, CURE is advancing this uniquely discrete, convenient and portable oral film product for achieving a better patient experience. The ’331 patent highlights several key aspects of the CUREfilm Blue™, such as a balance of performance characteristics (e.g., fast-dissolving and early onset of action) and physical parameters (e.g., large mass and small thickness), while it can be administered with or without water or beverage.

The global erectile dysfunction drug market is projected to grow at a CAGR of 6% and reach approximately USD$6.6 billion by 2025 with sildenafil representing a majority of the market, according to a report by QYR Research.

About CURE Pharmaceutical Holding Corp.

CURE Pharmaceutical^® is the pioneering developer of CUREform™, a patented drug delivery platform that offers a number of unique immediate- and controlled-release drug delivery vehicles designed to improve drug efficacy, safety, and patient experience for a wide range of active ingredients. As a vertically integrated company, CURE’s 25,000 square foot, FDA-registered, NSF^® and cGMP-certified manufacturing facility enables it to partner with pharmaceutical and wellness companies worldwide for private and white-labeled production. CURE has partnerships in the U.S., China, Mexico, Canada, Israel, and other markets in Europe.

Forward Looking Statement

Statements CURE makes in this press release may include statements which are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended (“Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (“Exchange Act”), which are usually identified by the use of words such as “anticipates,” “believes,” “estimates,” “expects,” “intends,” “may,” “plans,” “projects,” “seeks,” “should,” “will,” and variations of such words or similar expressions. CURE intends these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Exchange Act and is making this statement for purposes of complying with those safe harbor provisions. The forward-looking statements in this press release reflect CURE’s judgment as of the date of this press release. CURE disclaims any intent or obligation to update these forward-looking statements.

¹Viagra^® is a registered trademark of Pfizer Inc.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211116005048/en/

Investors:

Ina McGuinness

investor@curepharma.com

805.427.1372

Source: CURE Pharmaceutical Holding Corp.

FAQ

What is the significance of U.S. Patent No. 11,179,331 for CURR?

The patent provides CURE Pharmaceutical exclusive rights to its CUREfilm Blue™, enhancing its competitive edge in the erectile dysfunction market.

When will CUREfilm Blue™ be available for distribution?

The patent is set to issue on November 23, 2021, but the availability will depend on subsequent regulatory approvals.

What is CURE Pharmaceutical's product CUREfilm Blue™ used for?

CUREfilm Blue™ is an oral soluble film containing sildenafil citrate intended for treating erectile dysfunction.

How is the erectile dysfunction market projected to perform?

The global erectile dysfunction drug market is projected to grow at a CAGR of 6% and reach approximately USD$6.6 billion by 2025.

What technology does CUREfilm Blue™ use?

CUREfilm Blue™ uses the patented CUREfilm™ technology for fast-dissolving drug delivery.